Neoadjuvant cryotherapy improves dysphagia and may impact remission rates in advanced esophageal cancer

Abstract

Background and study aims Liquid nitrogen spray cryotherapy (LNSC) can provide rapid dysphagia relief, and is postulated to stimulate a local antitumor immune response. The aim of this prospective pilot clinical trial was to evaluate the safety and efficacy of LNSC when administered prior to chemoradiotherapy.

Patients and methods Treatment-naïve adult patients with dysphagia at the time of biopsy-proven squamous carcinoma or adenocarcinoma of the esophagus were prospectively enrolled at two tertiary medical centers. Patients underwent a single session of LNSC. The primary outcome measure was change in dysphagia at 1 and 2 weeks post-cryotherapy. A secondary outcome measure was clinical complete response rate (CR) following chemoradiotherapy.

Results Twenty-five patients were screened, of whom 21 patients were eligible and enrolled. There were seven with metastatic and 14 with locally advanced cancer. The primary outcome of dysphagia improvement of ≥ 1 point occurred in 15/21 patients (71 %) at 1 week, and 10/20 patients (50 %) at 2 weeks. The median dysphagia score improved by 1 at 1 week (P = 0.0003), and 0.5 at 2 weeks (P = 0.02). Six of nine patients (67 %) with locally advanced cancer who completed chemoradiation did not have residual tumor cells on mucosal biopsy, and five of nine patients (56 %) had a clinical CR. There were no serious cryotherapy-related complications.

Conclusions LNSC provided safe and effective palliation for esophageal cancer patients who presented with dysphagia at index diagnosis. Its combination with chemoradiotherapy did not lead to any serious toxicity. Our study provides a scientific rationale for pursuing larger clinical trials addressing synergistic effects of combining LNSC with chemoradiation.

• References

• 1 Ajani JA, D’Amico TA, Almhanna K. et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw 2015; 13: 194-227
• 2 Wang DB, Zhang X, Han HL. et al. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Dig Dis Sci 2012; 57: 3226-3233
• 3 Gkika E, Gauler T, Eberhardt W. et al. Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. Dis Esophagus 2014; 27: 678-684
• 4 van Hagen P, Hulshof MC, van Lanschot JJ. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
• 5 Francis SR, Orton A, Thorpe C. et al. Toxicity and outcomes in patients with and without esophageal stents in locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2017; 99: 884-894
• 6 Ohnmacht GA, Allen MS, Cassivi SD. et al. Percutaneous endoscopic gastrostomy risks rendering the gastric conduit unusable for esophagectomy. Dis Esophagus 2006; 19: 311-312
• 7 Greenwald BD, Dumot JA. Cryotherapy for Barrett’s esophagus and esophageal cancer. Curr Opin Gastroenterol 2011; 27: 363-367
• 8 Greenwald BD, Dumot JA, Horwhat JD. et al. Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus. Dis Esophagus 2010; 23: 13-19
• 9 Grana L, Ablin RJ, Goldman S. et al. Freezing of the esophagus: histological changes and immunological response. Int Surg 1981; 66: 295-301
• 10 Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 2009; 58: 1-11
• 11 Baust JG, Bischof JC, Jiang-Hughes S. et al. Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue. Prostate Cancer Prostatic Dis 2015; 18: 87-95
• 12 Barthel JS, Kucera S, Harris C. et al. Cryoablation of persistent Barrett’s epithelium after definitive chemoradiation therapy for esophageal adenocarcinoma. Gastrointest Endosc 2011; 74: 51-57
• 13 Dumot JA, Vargo JJ, Falk GW. et al. An open-label, prospective trial of cryospray ablation for Barrett’s esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 2009; 70: 635-644
• 14 Shaheen NJ, Greenwald BD, Peery AF. et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc 2010; 71: 680-685
• 15 Cash BD, Johnston LR, Johnston MH. Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus. World J Surg Oncol 2007; 5: 34
• 16 Goetz M, Malek NP, Kanz L. et al. Cryorecanalization for in-stent recanalization in the esophagus. Gastroenterology 2014; 146: 1168-1170
• 17 Kachaamy T, Prakash R, Kundranda M. et al. Liquid nitrogen spray cryotherapy for dysphagia palliation in patients with inoperable esophageal cancer. Gastrointest Endosc 2018; 88: 447-455
• 18 Mellow MH, Pinkas H. Endoscopic therapy for esophageal carcinoma with Nd:YAG laser: prospective evaluation of efficacy, complications, and survival. Gastrointest Endosc 1984; 30: 334-339
• 19 Ribeiro A, Bejarano P, Livingstone A. et al. Depth of injury caused by liquid nitrogen cryospray: study of human patients undergoing planned esophagectomy. Dig Dis Sci 2014; 59: 1296-1301
• 20 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
• 21 Chao YK, Wen YW, Chang HK. et al. An analysis of factors affecting the accuracy of endoscopic biopsy after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 2017; 43: 2366-2373
• 22 Kachaamy T, Shah T, Weber J. et al. Cryotherapy in combination with systemic chemotherapy for gastro-esophageal cancer palliation: chilling initial results, in Digestive Disease Week 2015. Gastrointestinal Endoscopy AB519 [unpublished abstract]
• 23 Divine G, Horton HJ, Hunt R. et al. Statistical grand rounds: a review of analysis and sample size calculation considerations for Wilcoxon tests. Anesth Analg 2013; 117: 699-710
• 24 Stahl M, Stuschke M, Lehmann N. et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317
• 25 Yu FJ, Shih HY, Wu CY. et al. Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: a comparison of nasogastric tube, esophageal stent, and ostomy tube feeding. Gastrointest Endosc 2018; 88: 21-31 e4
• 26 Lightdale CJ, Heier SK, Marcon NE. et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 1995; 42: 507-512
• 27 Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899
• 28 Gooden MJ, de Bock GH, Leffers N. et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103
• 29 Zhuo C, Xu Y, Ying M. et al. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer. Immunol Res 2015; 61: 338-347
• 30 Schneider PM, Metzger R, Schaefer H. et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 2008; 248: 902-908